Review

The Use of Iloprost in the Treatment of Bone Marrow Edema Syndrome of the Proximal Femur: A Review and Meta-Analysis

Timo Zippelius 1,*, Patrick Strube 2, Sebastian Rohe 2, Peter Schlattmann 3, Oliver Dobrindt 1, Thomas Caffard 1, Hassan Awan Malik 1, Chris Lindemann 2, Georg Matziolis 2 and Sabrina Böhle 2

1 Department of Orthopedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
2 Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany
3 Institute of Medical Statistics, Computer Sciences and Documentation, Jena University Hospital, 07743 Jena, Germany
* Correspondence: timo.zippelius@rku.de; Tel.: +49-(0)-731-177-5110 or 49-(0)-731-177-1969

Abstract: Objective: The aim of this meta-analysis was to investigate the impact of intravenous iloprost therapy on pain, function, edema changes, and follow-up surgery in bone marrow edema syndrome of the proximal femur. Methods: A systematic literature search up to May 2022 was performed to find relevant papers that made a statement about the outcome of intravenous iloprost therapy alone. Factors such as the Visual Analog Scale (VAS), Harris Hip Score (HHS), edema reduction, and follow-up interventions were considered. These were compared using Forest plots. Results: In 11 studies, 190 proximal femora with bone marrow edema syndrome that received intravenous iloprost therapy without further therapeutic intravenous or surgical intervention such as core decompression were studied. There was a significant mean improvement in VAS by 3.3 cm (2.07–4.5 cm) (p < 0.001) and HHS by 24.36 points (18.23–30.49) (p < 0.001) 3–6 months after receiving iloprost therapy. Only in 9.3% of cases (1.1–24.3%) did no clinical or radiological improvement occur. Conclusions: It could be shown that the existing publications support intravenous therapy with iloprost in patients with bone marrow edema syndrome and result in good clinical outcomes.

Keywords: ilomedin; iloprost; prostaglandin; bone marrow edema syndrome; femoral head necrosis; osteonecrosis; meta-analysis; review

1. Introduction

Bone marrow edema (BME) is a disease of the bones that involves significant pain and functional limitations [1]. In some cases, it progresses to avascular necrosis (AVN) or osteonecrosis (ON), which leads to destruction of the affected joint, so that rapid recognition and adequate treatment are essential not only to achieve pain relief but also to preserve the joint [1,2]. Especially in the early stages of ON, differentiation from bone marrow edema is difficult or impossible [3–6]. Numerous studies have suggested that there is no single pathomechanism for the onset of bone marrow edema (BMES), but a multifactorial etiology [1,7,8]. Although the exact mechanism remains unclear, there is increased fluid accumulation in the interstitial marrow space which is triggered by local venous pressure increase. Multiple causes can lead to a BME: trauma-induced, degenerative, inflammatory, ischemic, infectious, metabolic, iatrogenic or neoplastic lesions [9]. Moreover, there is some controversy over whether BME is a separate disease or an early stage of an AVN [5,10,11] that leads to change of the local microcirculation [12–14]. In the conservative treatment of BMES, there is a wide range of therapeutic options and medications. The various treatment options include mechanical unloading and pain management, magnetic therapy and extracorporeal shock wave therapy, and hyperbaric oxygen. The best-studied methods include mechanical unloading with the administration of bisphosphonates as well as the prostaglandin derivative iloprost (ilomedin) [15]. Numerous studies have demonstrated the beneficial effects of intravenous iloprost therapy in the treatment of the initial stage...
of osteonecrosis with BMES in various joints [1,2,6–8,16–21]. It should be noted that intravenous iloprost administration is an “off-label use” and should only be performed under inpatient conditions with circulatory monitoring [22]. The synthetic iloprost has the pharmacodynamic profile of the endogenous prostanoid, epoprostenol (PGI2; prostacyclin), which is a universal and potent inhibitor of platelet activation. Iloprost displays some fibrinolytic activity, decreases neutrophil adhesion and chemotaxis, is an arterial vasodilator and decreases peripheral vascular resistance and mean arterial blood pressure. This could be because of an increase in smooth muscle cAMP secondary to receptor activation, but the reason is controversial [23]. Regarding the pharmacokinetics, iloprost is completely metabolized by β-oxidation with 70% renal excretion of the metabolites and 12 to 17% faecal excretion [23].

The aim of this work was to perform a meta-analysis of available studies on the treatment of BMES with iloprost to further elucidate the effects on pain, function, MR-tomographic edema changes, and surgery rate.

2. Methods

2.1. Literature Search

A systematic electronic literature search was conducted via PubMed (National Library of Medicine) until May 2022 by two independent persons to find relevant papers on the treatment of BME with iloprost. For this purpose, the terms “ilomedin”, “iloprost”, “prostaglandin”, “prostacyclin”, “femoral”, “hip”, “edema”, and “bone marrow edema” in various combinations were searched without time limit. A full PubMed search string was added online. Moreover, all literature lists of the included trial articles were screened by two reviewers.

2.2. Inclusion Criteria

Once studies were identified, they were further filtered using the following inclusion criteria before analysis:

- Intravenous iloprost therapy alone;
- Localization of the BME at the proximal femur;
- German or English language;
- Documentation of HHS, pain on a VAS, or MRI findings over a period of at least one month;
- If applicable, documentation of surgery rate and conversion to total joint arthroplasty.

Studies that examined multiple groups or localizations were included if conclusions could be explicitly drawn regarding intravenous iloprost therapy alone at the proximal femur. With regard to the PICOS criteria, we proceeded as follows: all participating patients were diagnosed with bone marrow edema at the proximal femur with the intervention intravenous iloprost therapy alone and the documented outcome. A control group was not necessary. Regarding the study design, we included prospective, retrospective studies, long-term pilot studies, and case reports.

2.3. Data-Extraction

After selecting studies based on the in-/exclusion criteria, two investigators independently conducted data extraction. Attention was paid to the pain on a Visual Analog Scale (VAS) and the Harris Hip Score (HHS) to assess the change in pain with iloprost therapy. In addition, the outcome after therapy was assessed in terms of improvement in pain, function, MR-tomographic changes, and follow-up surgery such as decompression or even conversion to total hip arthroplasty.

The following outcomes were extracted from the studies by two independent reviewers using Excel:
- VAS (before and after intervention to form a delta VAS);
- HHS (before and after intervention to form a delta HHS);
- Named as nonresponders or, if not named, failures in terms of subjective or and
  MR-tomographic unchanged or worsened condition;
- Follow-up surgery including conversion to total joint arthroplasty.

2.4. Exclusion Criteria

Studies in which patients received additional surgical intervention such as core de-
compression or bisphosphonate therapy were excluded. Studies without documentation of
VAS or HHS, as well as without recording of these scores before intervention, or without
MR-tomographic evaluation, as well as studies without clear differentiation of results
regarding the proximal femur were also excluded.

2.5. Risk of Bias Assessment

Two investigators independently assessed the quality of the studies involved. Risk
of bias was assessed for each study using the Cochrane Risk of Bias Tool which included
seven sources of bias, including randomization process, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment, incomplete outcome data,
selective outcome reporting, and other potential bias [24]. Each study was examined based
on the above seven aspects and subsequently assessed as at low risk of bias, high risk of
bias, or unclear risk.

2.6. Meta Analysis

Studies were analyzed for statistical heterogeneity using an $I^2$ test. In case of ho-
mogeneity with low $I^2$, to obtain valid effect estimates, fixed-effects model was used for
evaluation. When heterogeneity was demonstrated, the random-effects model was used.
The results are presented graphically in Forest plots.

3. Results

3.1. Identification and Selection of Study Data and Study Characteristics

The online search using iloprost alone yielded more than 2900 papers. Combining
the above keywords yielded 37 relevant clinical studies, including one dissertation that ad-
dressed iloprost therapy as part of prospective, retrospective study, long-term pilot studies,
and case reports. Eleven studies met the inclusion criteria (Figure 1, Table 1) [2,6,18,25–32].
Twenty-six studies were excluded (see Table 2). These were predominantly retrospective
studies. In addition, the 11 studies were published between 2004 and 2018 in German [32]
or in English. A total of 190 proximal femora were studied because some patients had a di-
agnosis of femoral head necrosis bilaterally. On average, 31.5% of the patients were women
and 68.5% were men, excluding the study by Jäger et al. 2008 as no exact allocation could
be made for the 42 proximal femora affected in the 50 patients. The side effects mentioned
in the studies with symptoms such as flushing, headache, or nausea were relatively mild,
so only one patient had to discontinue the intervention in the 11 studies mentioned.
Table 1. Literature analysis of the included studies.

| Author          | Year | Study Design | Number of Proximal Femora | Gender | Dose                        | MRI Result                          | Failure                      | Control Group     | Control after | Follow-Up | Partial Load | Besonderheit                           | VAS | HHS |
|-----------------|------|--------------|----------------------------|--------|-----------------------------|-------------------------------------|------------------------------|-------------------|---------------|-----------|--------------|----------------------------------------|-----|-----|
| Zippelius [2]   | 2018 | retrospective | 19                         | 7 women, 12 men | 0.5 ng/kg/min over 6 h over 5 days | After 3 months: 15/19 complete edema regression | 4 surgeries (2× cannulation, 2× TEP) | /                 | 3, approx. 29 months | 29 ± 11 months | 6 weeks | X only after 29 months | X only after 29 months |       |     |
| Meizer [25]     | 2009 | retrospective | 27                         | 8 women, 19 men | 50–20 µg over 6 h for 5 days, start with 50, reduce if needed | After 4 months: 20/27 improved on MRI, unchanged, 3 worsened | 7 nonresponders (named) | /                 | 4 months | 4 months | 3 weeks | 81% less pain at rest, 63% less activity pain | Other score | -    |
| Aigner [26]     | 2005 | retrospective | 18                         | 4 women, 13 men | 20 µg over 6 h for 5 days | After 3 months: Complete edema regression in all femora | /                            | Core decompression group | 3, 12 months | 11 months | Partial (for 5 patients for 3 weeks) | In the iloprost group, one patient had to discontinue treatment due to severe headache (n post: 17 femora) | -    |     |
| Beckmann [18]   | 2013 | retrospective | 12                         | 3 women, 9 men | 20–40 µg over 6 h for 5 days, day 1 20 µg, day 2 30 µg, day 3–5 40 µg | After 3 months: Reduction from BME, not from ON | 2 nonresponders by pain indication (named) | Core decompression, core decompression with ilomedin | 3, 12 months | 13 months (11–16) (all groups) | 6 weeks | The combination of iloprost and tapping shows the best results | X after 3 months | X after 3 months |     |
| Aigner [27]     | 2009 | prospective  | 8                          | 6 women | 20 µg over 6 h for 5 days, start 10 days after birth | After 3 months: Complete remission in 5, subtotal in 1 pat (all BME) No progression at last follow-up | /                            | /                 | 1, 3 months | 31 months (14–43) | unknown | All six subjects improved immediately during the first 2 weeks after initiation of intravenous therapy | X after 3 months at rest | -    |     |
| Disch [28]      | 2004 | Case Report  | 2                          | 1 man (with sickle cell anaemia) | 0.5–1.0 µg/kg/min over 6 h/d for 5 days, day 1 0.5 µg, day 2 0.75 µg, day 3–5 1 µg | After 3 months: Significant reduction of edema in both femora | /                            | /                 | 1, 3 months | 3 months | unknown | Already after the 3rd day less pain. Further improvement in the next 4 weeks regarding ROM | -   | X after 1 month |
Table 1. Cont.

| Author         | Year   | Study Design       | Number of Proximal Femora | Gender | Dose                                      | MRI Result                                      | Failure | Control Group | Control after | Follow-Up | Partial Load | Besonderheit                  | VAS | HHS |
|----------------|--------|--------------------|---------------------------|--------|------------------------------------------|--------------------------------------------------|---------|---------------|---------------|-----------|--------------|----------------------------------|-----|-----|
| Meini, Pani-gada [29] | 2012   | Case Report        | 1                         | 1 woman | 2 ng/kg/min over 6 h for 5 days, after 4 weeks repeat with 1.5 ng/kg/min over 6 h for 5 days | After 4 weeks, reduction of edema, then iloprost again. Then, after 4 weeks, further reduction; after three more months, control/complete remission | /       | /             | 1, 2, 5 months after first treatment | 5 months after first treatment | unknown | During treatment with iloprost from the third day significant reduction of pain and joint dysfunction | X after second therapy | X after second therapy |
| Jäger [30] 1 | 2008   | prospective        | 42                        | 28 women, 22 men (total 117 bones) | 0.5–1.0 ng/kg/min over 6 h for 5 days | Significant reduction of edema after 3 and 6 months. After 6 months, complete regression in 65 of 117 bones. Advanced ARCO stages (III, IV) were not affected by iloprost | /       | /             | 5 days, 3, 6 months | unknown | X VAS in all bones | X after 3 months |
| Petje [31]   | 2004   | Long-term pilot study | 11                        | 3 women, 4 men | 2 ng/kg/min over 6 h for 5 days | ON progression in 2 patients | /       | /             | 32 months (12–48) all bones (45 patients) | unknown | - | - |
| Disch [6]    | 2005   | prospective, case-controlled | 40                        | 7 women, 26 men | 0.5–1.0 µg/kg/min over 6 h/d for 5 days; day 1 0.5 µg, day 2 0.75, day 3–5 1 µg | Edema reduction in all patients after 3 months | /       | /             | 1.3, and approx. 25 months | 25 months (11–37) | unknown | Group I: 16 isolated BME (ARCO I), Group II: 17 ON (ARCO II, III) | X after 3 months | X after 3 months |
| Jäger [32]   | 2004   | prospective        | 10                        | 2 women, 5 men (total 20 bones) | Unknown dose for 5 days | After 3 months, reduction in 4 proximal femora, no change in another 4, and in 2 (the latter already previously ARCO III & IV) | 6 after MRI | 3 months | 3 months | unknown | unknown | Yes, but all joints at VAS | - |

1 In this study, 50 patients with 117 affected bones were examined. Of these, 42 bones were proximal femora. A precise assignment of sexes to femora was not made.
Figure 1. Flow Chart of inclusion of studies for the meta-analysis.

Table 2. Excluded studies.

| Author                  | Year | Reason for Exclusion                                      |
|-------------------------|------|-----------------------------------------------------------|
| Aigner [33]             | 2001 | Location (talus)                                         |
| Aigner [34]             | 2002 | Location (forefoot)                                       |
| Aigner [3]              | 2002 | Location (acetabulum)                                     |
| Aigner [35]             | 2003 | Location (hindfoot)                                       |
| Aigner [36]             | 2005 | Location (foot)                                           |
| Aigner [37]             | 2008 | Location (knee)                                           |
| Anagnostakos [38]       | 2013 | No clear differentiation of results regarding the proximal femur (21 bones) |
| Arazi [39]              | 2006 | Location (ankle)                                          |
| Arazi [40]              | 2011 | Location (os metatarsale)                                 |
| Baier [41]              | 2013 | Location (knee, foot)                                     |
| Claßen [20]             | 2016 | No clear differentiation of results regarding the proximal femur (136 bones) |
| Hörterer [42]           | 2018 | Location (foot, ankle)                                    |
| Huang [43]              | 2020 | No treatment with iloprost                                |
| Jäger [44]              | 2009 | 3 out of 8 patients had a core decompression, no clear differentiation |
| Jäger [17]              | 2011 | No clear differentiation of results regarding the proximal femur (20 bones) |
| Lackner [45]            | 2005 | Observational Study: 3 out of 9 patients with iloprost without a clear differentiation |
| Mahmoudi (dissertation) [46] | 2009 | Most likely the same cohort as Jäger 2008, co-author      |
| Mayerhoefer [47]        | 2007 | Location (knee)                                           |
| Mayerhoefer [48]        | 2008 | Location (knee)                                           |
| Meizer [12]             | 2005 | No clear differentiation of results regarding the proximal femur (104 bones) |
Table 2. Cont.

| Author        | Year  | Reason for Exclusion                                                                 |
|---------------|-------|---------------------------------------------------------------------------------------|
| Petje [49]    | 2002  | No scores, no clear differentiation                                                   |
| Pilge [50]    | 2016  | Ilomedin therapy with core decompression and bone marrow aspirate                      |
| Rühner [7]    | 2014  | Location (foot, ankle)                                                                  |
| Tillmann [51] | 2007  | Location (knee, foot)                                                                  |
| Tosun [52]    | 2020  | No clear differentiation of results regarding the proximal femur (23 bones)             |
| Zippelius [8] | 2018  | Location (knee)                                                                        |

3.2. Risk of Bias

Figure 2 presents the summary of the risk of bias for each included study.

Figure 2. Risk of bias for each study. Legend: red, high risk; Yellow, unclear risk; green, low risk [2,6,18,25–32].
3.3. Heterogeneity of Included Studies

As a result of the heterogeneity tests, the study results were homogeneous with regard to conversion to total hip arthroplasty ($I^2 = 0\%$) and reoperations such as Salter’s osteotomy, femoral varization osteotomy, or core decompression ($I^2 = 16.1\%$). Measurements of improvement after iloprost therapy in terms of MR-tomographic edema reduction and subjective sensation as well as HHS and VAS before and after therapy showed significant heterogeneity. Therefore, 77.3–88.4\% can be attributed to mathematical study heterogeneity rather than random sample variance. To account for these differences, a random-effects model was used to perform the calculation [53].

3.4. Therapeutic Effects after Intervention with Iloprost

For subjective assessment of pain, the VAS was determined in some studies before and after intravenous iloprost therapy ($n = 7$). Of these, three studies were excluded in which either multiple bones were examined and the VAS could not be related to the proximal femora alone [30,32] or in which the VAS was determined only after the second iloprost therapy [29]. The study regarding the improvement of pain by the intervention (delta VAS) showed a significant improvement of 3.3 cm (2.07–4.5 cm) (Figure 3). Except for the study by Zippelius et al., in which the VAS was only determined after approximately 29 months [2], the postintervention VAS comparison was made after three months. Some studies also determined further time points, which, however, did not produce any significant changes. The study by Aigner et al. was divided into pain at rest and pain on effort. Pain at rest was used [27]. Zippelius, Disch and Beckmann did not provide any information regarding the exact pain domain [2,6,18].

![Figure 3](image3.png)

**Figure 3.** Forest plot showing the effect of iloprost therapy on the Visual Analog Scale (VAS) for pain. There was a significant difference ($p < 0.01$) [2,6,18,27].

![Figure 4](image4.png)

**Figure 4.** Forest plot showing the effect of iloprost therapy on Harris Hip Score (HHS). There was a significant difference ($p < 0.01$) [2,6,18,27,28,30].

In some studies ($n = 7$), the HHS was determined as a combination of subjective and objective assessment criteria with additional parameters such as function, function in everyday life, and physical examination, in addition to pain. Again, one study was excluded in which the HHS was determined only after the second therapy [29]. The HHS
improved on average by 24.36 points (18.23–30.49) (Figure 4). For a more accurate influence in the meta-analysis, the time of HHS determination after three months could be used in most studies, as with the VAS. Again, the study of Zippelius et al. with the long-term influence of about 29 months [2] as well as the study of Disch et al. 2004 with one month follow-up differed [28].

Of the proximal femora examined as “non-responders”, 9.3% did not improve in terms of pain and/or MRI findings after the treatment (1.1–24.3%) (Figure 5). The study by Jäger et al. 2008 was not included in the determination of improvement because the proximal femora could not be precisely identified. However, it is known that 15 joints of stages ARCO III and IV were not affected [30]. Intravenous iloprost therapy improved the bone marrow edema syndrome in 90.7% (75.7–98.9%, \( p < 0.01 \)). Overall, 1.9% of proximal femora underwent hip preservation surgery (0–5.9%) (Figure 6) which can be broken down into one Salter’s osteotomy, one femoral varization osteotomy, and two core decompression procedures. A total of 0.6% of all proximal femora previously treated with iloprost without concomitant surgical intervention were converted to total arthroplasty during follow-up (0–3.4%, \( n = 2 \)) (Figure 7).

---

**Table 1:**

| Study            | Events | Total | Proportion | 95%–CI       | Weight (fixed) | Weight (random) |
|------------------|--------|-------|------------|--------------|----------------|----------------|
| Zippelius 2018   | 4      | 19    | 0.21       | [0.06; 0.46] | 12.9%          | 11.9%          |
| Meizer 2009      | 17     | 27    | 0.26       | [0.11; 0.46] | 18.4%          | 12.4%          |
| Agner 2005       | 0      | 17    | 0.00       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Beckmann 2013    | 2      | 12    | 0.17       | [0.02; 0.48] | 5.4%           | 10.0%          |
| Aigner 2009      | 0      | 17    | 0.00       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Disch 2004       | 1      | 2     | 0.09       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Meini, Panigada 2012 | 0   | 10    | 0.06       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Jaeger 2004      | 1      | 12    | 0.08       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Petje 2004       | 1      | 11    | 0.09       | [0.00; 0.20] | 11.6%          | 11.6%          |
| Disch 2005       | 0      | 10    | 0.00       | [0.00; 0.20] | 11.6%          | 11.6%          |

**Figure 5.** Forest plot showing the treatment failures after iloprost therapy for the treatment of bone marrow edema syndrome in terms of subjective pain relief and/or edema reduction on MRI. There was a significant difference (\( p < 0.01 \)) [2,6,18,25–29,31,32].

**Figure 6.** Forest plot showing hip joint preservation surgery after intravenous iloprost therapy [2,6,27–29,31].
weight-adapted dose increase was recommended by Beckmann et al. with day 1 $20 \mu g/kg$, possible dose reduction to $20 \mu g$ in the event of side effects [25]. Weight-adapted constant doses were used by Zippelius et al. with $0.5 \text{ng/kg}$ [2], Petje et al. with $2 \text{ng/kg}$ [31] and Meini-Panigada et al. with $2 \text{ng/kg}$ and repeated after 4 weeks with $1.5 \text{ng/kg}$ [29]. A weight-adapted dose increase was recommended by Beckmann et al. with day 1 $20 \mu g/kg$, day 2 $30 \mu g/kg$, day 3–5 $40 \mu g/kg$ by Beckmann et al. [18] and with day 1 $0.5 \mu g$, day 2 $0.75 \mu g$, day 3–5 $1 \mu g/kg$ by Jäger et al. and Disch et al. [6,28,30]. One dosage remains unchanged but there was a clear pain response. Therefore, only the two nonresponders mentioned in the study were used in the present evaluation. However, it must be critically discussed whether the six MRI-tomographically unchanged or progressive proximal femora mentioned in the study should have been used for standardization [18]. Furthermore, in Jäger et al. 2004, nonresponse to therapy could be determined exclusively via MRI diagnostics, which, according to the VAS, affected all 20 bones examined (10 of which were proximal femora) [32].

Even though all studies were calculated with an iloprost therapy over 6 h for five days, the doses were not the same in all studies, since in some cases treatment involved a constant dose, a dose reduction in case of side effects, or an increased dose over the therapy period. In addition, the studies diverged with regard to the loading of the affected hip after therapy between full loading and partial loading for up to six weeks. Constant doses were administered in the following studies and can be divided into weight-independent and weight-adapted studies: Aigner et al. used $20 \mu g$ [26,27] and Meizer et al. $50 \mu g$ with a possible dose reduction to $20 \mu g$ in the event of side effects [25]. Weight-adapted constant doses were used by Zippelius et al. with $0.5 \text{ng/kg}$ [2], Petje et al. with $2 \text{ng/kg}$ [31] and Meini-Panigada et al. with $2 \text{ng/kg}$ and repeated after 4 weeks with $1.5 \text{ng/kg}$ [29]. A weight-adapted dose increase was recommended by Beckmann et al. with day 1 $20 \mu g/kg$, day 2 $30 \mu g/kg$, day 3–5 $40 \mu g/kg$ by Beckmann et al. [18] and with day 1 $0.5 \mu g$, day 2 $0.75 \mu g$, day 3–5 $1 \mu g/kg$ by Jäger et al. and Disch et al. [6,28,30].

Figure 7. Forest plot showing the conversion to total hip arthroplasty [2,6,27–29,31].

4. Discussion

The aim of the present meta-analysis was to investigate the influence of intravenous iloprost therapy on pain, function, and follow-up surgery in bone marrow edema syndrome of the proximal femur. The meta-analysis of the 11 included studies showed subjective relief of symptoms and/or edema reduction on MRI of bone marrow edema syndrome in 90.7% of cases with singular iloprost therapy ($75.7–98.9\%$, $p < 0.01$). Twenty-one of 190 proximal femora did not respond to iloprost therapy, and six of these underwent surgical intervention after therapy (3.2%). The 2008 study by Jäger et al. was only included in the calculation of the HHS, but not in the further statistical analyses as no precise delineation could be performed here for all 117 bones studied [30]. Pain relief with iloprost therapy occurred in many cases during the five-day administration [6,28,29].

Nevertheless, the included studies show heterogeneity in some characteristics, which complicates the interpretation of the results. The nonresponders were identified differently in the individual studies: while in Zippelius et al. as well as Petje et al. these nonresponders were defined by MRI progression as well as follow-up surgery [2,31], the others in Meizer et al. and Beckmann et al. were directly labeled as nonresponders in the respective study [18,25]. It is important to emphasize here that Meizer et al. defined seven nonresponders by a nonresponse MR-tomographically [25], whereas Beckmann et al. no longer considered these proximal femora as nonresponders if the findings on MRI were unchanged but there was a clear pain response. Therefore, only the two nonresponders mentioned in the study were used in the present evaluation. However, it must be critically discussed whether the six MRI-tomographically unchanged or progressive proximal femora mentioned in the study should have been used for standardization [18]. Furthermore, in Jäger et al. 2004, nonresponse to therapy could be determined exclusively via MRI diagnostics, which, according to the VAS, affected all 20 bones examined (10 of which were proximal femora) [32].
unknown [32]. Frequently, no information was provided regarding postinterventional mobilization. To obtain valid effect estimates, the random-effects model was used with regard to improvement after iloprost therapy as well as HHS and VAS before and after therapy. In Meini et al., a case report was made of a patient who received iloprost therapy again after four weeks. Edema reduction and relief of symptoms were already achieved after the first therapy. However, because only a short-term statement of a singular iloprost therapy could be made, VAS and HHS were not included in our statistical analysis [29]. In addition, we cannot exclude the possibility that co-authorships used the same patient population to generate the study. Likewise, the studies measured different follow-up periods (3–32 months), so possible further follow-up surgeries as well as conversions to total hip arthroplasty could have occurred.

A limitation of the meta-analysis is the small number of patients; higher patient numbers and further long-term results are required for definitive conclusions. There was no a priori protocol. In addition, the different patient populations with femoral head necrosis from I to IV according to the Association Research Circulation Osseous (ARCO) staging is a fundamental limitation, as the 2015 S3 guideline recommends iloprost therapy only for stage I and II [19]. Therefore, some studies such as Zippelius et al. excluded ARCO III and IV [8]. Jäger et al., for example, also investigated therapy in ARCO stages III (n = 9) and IV (n = 1), among others [30]. However, in the study by Beckmann et al., it was interesting to note that one of two nonresponders with a hip with ON (ARCO II) who failed to improve at an early stage had been successfully treated with iloprost six months earlier due to contralateral BME [18]. With monotherapy with iloprost as well as with decompression of ON, the results were not as promising as with BME [18]. Nevertheless, iloprost was shown to be an option to achieve pain relief and mobilization, even at higher ARCO stages. Here, however, iloprost therapy should be seen as part of a conservative treatment regimen and supplemented by other measures if necessary [6].

In summary, there is a discrete improvement in bone marrow edema syndrome with intravenous iloprost therapy alone. In most studies, this effect occurs within the first days or weeks. According to Aigner et al., a comparison of core decompression with singular iloprost therapy showed equally good results (n = 20 vs. n = 18) [26]. According to Beckmann et al., the combination of intravenous iloprost and retrograde tapping seems to be the most promising treatment method compared with iloprost therapy or tapping alone (n = 12 per group). Although improvement in HHS, WOMAC score, SF-36 score, and VAS was shown three months and one year after therapeutic intervention, the greatest effects were obtained with the combination [18]. Thus, it can be concluded that intravenous iloprost therapy has a positive effect on bone marrow edema syndrome in the proximal femur, but may not always be accompanied by edema reduction on MRI, improvement in hip joint function, and/or pain reduction, especially in later ARCO stages.

This study has limitations. Two reviewers using the protocol for inclusion and exclusion criteria thoroughly examined the studies and carefully identified specific study designs, biases within studies, differences between studies, and reporting biases. However, it must be said that the literature that accurately address the stated topic and allows for analysis is limited, as evidenced by the number of studies included.

5. Conclusions

Intravenous iloprost therapy has an impact on bone marrow edema syndrome in the proximal femur. It can produce a reduction in pain, improvement in function, and MR-tomographic reduction in the extent of edema.

Author Contributions: Conceptualization, T.Z. and G.M.; methodology, G.M. and P.S. (Peter Schlattmann); software, P.S. (Patrick Strube), O.D. and P.S. (Peter Schlattmann); validation, C.L., H.A.M. and T.C.; study search and data extraction T.Z. and S.B., formal analysis, S.R.; investigation, S.B. and T.Z.; resources, P.S. (Patrick Strube); data curation, P.S. (Patrick Strube) and G.M.; writing—original draft preparation, T.Z. and S.B.; writing—review and editing, T.Z., S.B. and P.S. (Patrick Strube); visualization, P.S. (Patrick Strube), supervision, G.M. and T.Z.; project administration, G.M.; fund-
ing acquisition, G.M. and T.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Poutous, I.; Giannoudis, P.V. The role of iloprost on bone edema and osteonecrosis: Safety and clinical results. Expert Opin. Drug Saf. 2018, 17, 225–233. [CrossRef] [PubMed]
2. Zippelius, T.; Perka, C.; Preininger, B.; Matziolis, G.; Strube, P.; Röhner, E. Long-term effects of intravenous iloprost therapy in patients with bone marrow oedema of the hip. Acta Orthop. Belg. 2018, 84, 172–178. [PubMed]
3. Aigner, N.; Petje, G.; Schneider, W.; Krasny, C.; Grill, F.; Landsiedl, F. Juvenile bone-marrow oedema of the acetabulum treated by iloprost. J. Bone Jt. Surg. Br. Vol. 2002, 84, 1050–1052. [CrossRef]
4. Aigner, N.; Schneider, W.; Eberl, V.; Knahr, K. Core decompression in early stages of femoral head osteonecrosis—An MRI-controlled study. Int. Orthop. 2002, 26, 31–35. [CrossRef]
5. Hofmann, S. The painful bone marrow edema syndrome of the hip joint. Wien. Klin. Wochenschr. 2005, 117, 111–120. [CrossRef]
6. Disch, A.C.; Matziolis, G.; Perka, C. The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J. Bone Jt. Surg. Br. Vol. 2005, 87, 560–564. [CrossRef]
7. Röhner, E.; Zippelius, T.; Steinidl, D.; Fussi, J.; Perka, C. Effects of intravenous iloprost therapy in patients with bone marrow oedema of the foot and ankle. Eur. J. Orthop. Surg. Traumatol. 2013, 24, 1609–1616. [CrossRef]
8. Zippelius, T.; Matziolis, G.; Perka, C.; Putzier, M.; Strube, P.; Röhner, E. Long-Term Effects of Intravenous Iloprost Therapy in Patients with Bone Marrow Oedema of the Knee Joint. Acta Chir. Orthop. Traumatol. Cechoslov. 2018, 85, 17–21.
9. Starr, A.M.; Wessely, M.A.; Albastaki, U.; Pierre-Jerome, C.; Kettner, N.W. Bone marrow edema: Pathophysiology, differential diagnosis, and imaging. Acta Radiol. 2008, 49, 771–786. [CrossRef]
10. Hofmann, S.; Kramer, J.; Vakil-Adli, A.; Aigner, N.; Breitenseheer, M. Painful bone marrow edema of the knee: Differential diagnosis and therapeutic concepts. Orthop. Clin. N. Am. 2004, 35, 321–333. [CrossRef]
11. Jones, J. Osteonecrosis and bone marrow edema syndrome: Similar etiology but a different pathogenesis. In Osteonecrosis: Etiology, Diagnosis, and Treatment; Urbaniaik, J.R., Jones, J.P., Eds.; American Academy of Orthopaedic Surgeons: Rosemont, IL, USA, 1997; pp. 181–187.
12. Meizer, R.; Radda, C.; Stolz, G.; Kotsaris, S.; Petje, G.; Krasny, C.; Wilk, M.; Mayet rhöfer, M.; Landsiedl, F.; Aigner, N. MRI-controlled analysis of 104 patients with painful bone marrow edema in different joint localizations treated with the prostacyclin analogue iloprost. Wien. Klin. Wochenschr. 2005, 117, 278–286. [CrossRef]
13. Breitenseheer, M.J.; Kramer, J.; Mayerherofer, M.E.; Aigner, N.; Hofmann, S. Differential diagnosis of bone marrow edema of the knee joint. Radioloe 2006, 46, 46–56. [CrossRef]
14. Schmitt-Sody, M.; Kirchhoff, C.; Mayer, W.; Goebel, M.; Jansson, V. Avascular necrosis of the femoral head: Inter- and intraobserver variations of Ficat and ARCO classifications. Int. Orthop. 2008, 32, 283–287. [CrossRef] [PubMed]
15. Hofmann, S.; Mazieres, B. Osteonecrosis: Natural course and conservative therapy. Orthopade 2000, 29, 403–410. [PubMed]
16. Zippelius, T.; Hoff, P.; Strube, P.; Schiffern, R.; Maslaris, A.; Matziolis, G.; Röhner, E. Effects of iloprost on human mature osteoblasts in vitro. J. Back Musculoskelet. Rehabil. 2012, 32, 897–903. [CrossRef]
17. Jäger, M.; Zilkens, C.; Bittersohl, B.; Matheney, T.; Kozina, G.; Blondin, D.; Krauspe, R. Efficiency of iloprost treatment for osseous malperfusion. Int. Orthop. 2010, 35, 761–765. [CrossRef]
18. Beckmann, J.; Schmidt, T.; Schaumberger, J.; Rath, B.; Lüiring, C.; Tingart, M.; Gritka, J. Infusion, core decompression, or infusion following core decompression in the treatment of bone edema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol. Int. 2012, 33, 1561–1565. [CrossRef]
19. Roth, A.; Beckmann, J.; Smolenski, U.; Fischer, A.; Jäger, M.; Tingart, M.; Rader, C.; Peters, K.M.; Reppenhagen, S.; Nöth, U.; et al. S3 guideline. Part 2: Non-traumatic avascular femoral head necrosis in adults—untreated course and conservative treatment. Z. Orthop. Unf. 2015, 153, 488–497.
20. Claßen, T.; Becker, A.; Landgraebner, S.; Haversath, M.; Li, X.; Zilkens, C.; Krauspe, R.; Jäger, M. Long-term clinical results after iloprost treatment for bone marrow edema and avascular necrosis. Orthop. Rev. 2016, 8, 6150. [CrossRef]
21. Ghasemi, R.A.; Sadeghi, S.; Rahimee, N.; Tahmasebi, M. Technologies in the Treatment of Bone Marrow Edema Syndrome. Orthop. Clin. N. Am. 2018, 50, 131–138. [CrossRef]
22. Maus, U.; Flechtenmacher, J.; Peters, K.M. Conservative treatment of atraumatic femoral head necrosis. Orthopade 2018, 47, 735–744. [CrossRef] [PubMed]
23. Grant, S.M.; Goa, K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992, 43, 889–924. [CrossRef]
24. Cumpton, M.; Li, T.; Page, M.J.; Chandler, J.; Welch, V.A.; Higgins, J.P.; Thomas, J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 2019, 10, ED000142. [CrossRef]
25. Meiner, R.; Meiner, D.; Meiner, E.; Radziki, C.; Lantsiedel, F.; Aigner, N. Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost. Indian J. Orthop. 2009, 43, 36–39. [CrossRef] [PubMed]

26. Aigner, N.; Petje, G.; Schneider, W.; Meier, R.; Wilk, M.; Kotsiaris, S.; Knahr, K.; Lantsiedel, F. Bone marrow edema syndrome of the femoral head: Treatment with the prostacyclin analogue iloprost vs. core decompression: An MRI-controlled study. Wien. Klin. Wochenschr. 2005, 117, 130–135. [CrossRef] [PubMed]

27. Aigner, N.; Meier, R.; Lantsiedel, D.; Becker, S.; Meier, E.; Lantsiedel, F. Bone Marrow Edema Syndrome in Postpartal Women: Treatment with Iloprost. Orthop. Clin. N. Am. 2009, 40, 241–247. [CrossRef]

28. Disch, A.C.; Matziolis, G.; Reinke, P.; Perka, C. Intravenous Iloprost treatment for severe bone pain caused by sickle cell crisis. Thromb. Haemost. 2004, 91, 1047–1049. [PubMed]

29. Meini, S.; Panigada, G. Proposal of early retreatment with iloprost in partially responsive patients with bone marrow edema syndrome: A case report. Ital. J. Med. 2012, 6, 332–337. [CrossRef]

30. Jäger, M.; Tillmann, F.P.; Thorns, T.S.; Mahmoudi, M.; Blondin, D.; Hetzel, G.R.; Zilkens, C.; Krauspe, R. Rationale for prostaglandin I2 in bone marrow oedema—from theory to application. Arthritis Res. Ther. 2006, 8, R120. [CrossRef]

31. Petje, G.; Radler, C.; Aigner, N.; Ranner, H.; Krieg, G.; Grill, F. Pharmacological management of aseptic osteonecrosis in children. Expert Opin. Pharmacother. 2004, 5, 1455–1462. [CrossRef]

32. Jäger, M.; Werner, A.; Lentrod, S.; Model, U.; Krauspe, R. Pain management in non-juvenile, aseptic osteonecrosis. Schmerz 2004, 18, 481–491.

33. Aigner, N.; Meier, R.; Steinecke, G.; Schröder, W.; Krash, C.; Lantsiedel, F. Treatment of bone-marrow edema of the talus with the prostacyclin analogue iloprost. An MRI-controlled investigation of a new method. J. Bone Jt. Surg. Br. Vol. 2001, 83, 859–858. [CrossRef]

34. Aigner, N.; Petje, G.; Steinboeck, G.; Schröder, W.; Krash, C.; Lantsiedel, F. Bone Marrow Edema of the Forefoot after a Chevignon Osteotomy—A Rare Cause of Metatarsalgia: A Case Report. Foot Ankle Int. 2002, 23, 447–451. [CrossRef] [PubMed]

35. Aigner, N.; Meier, R.; Stolz, G.; Petje, G.; Krash, C.; Lantsiedel, F.; Steinboeck, G. Iloprost for the treatment of bone marrow edema in the hindfoot. Foot Ankle Clin. 2003, 8, 683–693. [CrossRef]

36. Aigner, N.; Radda, C.; Meier, R.; Petje, G.; Kotsiari, S.; Krash, C.; Lantsiedel, F.; Steinboeck, G. Bone marrow edema in the foot—MRI findings after conservative therapy. Foot Ankle Surg. 2005, 11, 87–91. [CrossRef]

37. Aigner, N.; Meier, R.; Petje, G.; Meier, E.; Abdulakafy, A.; Lantsiedel, F. Natural course of intra-articular shifting bone marrow edema syndrome of the knee. BMC Muscleskelet. Disord. 2008, 9, 45. [CrossRef] [PubMed]

38. Anagnostos, K.; Orth, P. Role of Serum Lipoprotein at the Site of Iloprost Therapy in the Treatment of Painful Bone Marrow Edema. Orthopedics 2013, 36, e1283–e1289. [CrossRef] [PubMed]

39. Arazi, M.; Yel, M.; Uguz, B.; Emlik, D. Be aware of bone marrow edema syndrome in ankle arthroscopy: A case successfully treated with iloprost. Arthroscopy 2006, 22, 909.e1–909.e3. [CrossRef]

40. Arazi, M.; Kiresi, D. Bone marrow edema syndrome of the third metatarsal bone: A rare cause of metatarsalgia treated with iloprost. Eur. J. Orthop. Surg. Traumatol. 2010, 21, 59–62. [CrossRef]

41. Baier, C.; Schaumburger, J.; Gottes, J.; Heers, G.; Schmidt, T.; Griko, J.; Beckmann, J. Bisphosphonates or prostacyclin in the treatment of bone-marrow edema syndrome of the knee and foot. Rheumatol. Int. 2012, 33, 1397–1402. [CrossRef]

42. Hörter, H.; Baumbach, S.F.; Gregersen, J.; Kriegelstein, S.; Gottschalk, O.; Szeimies, U.; Walther, M. Treatment of Bone Marrow Edema of the Foot and Ankle With the Prostacyclin Analog Iloprost. Foot Ankle Int. 2018, 39, 1183–1191. [CrossRef]

43. Huang, Y.-G.; Chia, W.K.; Jin, D.; Gao, Y.; Sheng, J.; Zhang, C. Bone marrow lesion on magnetic resonance imaging indicates the last chance for hip osteonecrosis treated with vascularized fibular grafting before collapse. Int. Orthop. 2020, 44, 2529–2536. [CrossRef] [PubMed]

44. Jäger, M.; Zilkens, C.; Westhoff, B.; Jelinek, E.M.; Kozina, G.; Krauspe, R. Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer. Anticancer Res. 2009, 29, 3433–3440. [PubMed]

45. Lackner, H.; Benesch, M.; Moser, A.; Sombli-Müttner, F.; Linhart, W.; Raith, J.; Urban, C. Aseptic osteonecrosis in children and adolescents treated for hematologic malignancies: A 13-year longitudinal observational study. J. Pediatr. Hematol. Oncol. 2005, 27, 259–263. [CrossRef] [PubMed]

46. Mahmoudi, M. Therapie der Nicht-Juvenilen, Aseptischen Osteonekrose und des Symptomatischen Knochenmarködems mit dem Prostazykin-Analogon Iloprost: Eie MRT-Kontrollierte Klinische. Ph.D. Thesis, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, 2009.

47. Mayerhöfer, M.E.; Kramer, J.; Breitenseher, M.J.; Norden, C.; Vakil-Adli, A.; Hofmann, S.; Meier, R.; Siedentop, H.; Lantsiedel, F.; Aigner, N. Short-term outcome of painful bone marrow oedema of the knee following oral treatment with iloprost or tramadol: Results of an exploratory phase II study of 41 patients. Rheumatology 2007, 46, 1460–1465. [CrossRef]

48. Mayerhöfer, M.E.; Kramer, J.; Breitenseher, M.J.; Norden, C.; Vakil-Adli, A.; Hofmann, S.; Meier, R.; Siedentop, H.; Lantsiedel, F.; Aigner, N. MRI-demonstrated outcome of subchondral stress fractures of the knee after treatment with iloprost or tramadol: Observations in 14 patients. Clin. J. Sport Med. 2008, 18, 358–362. [CrossRef] [PubMed]

49. Petje, G.; Radler, C.; Aigner, N.; Kriegs-Au, G.; Ganger, R.; Grill, F. Aseptic osteonecrosis in childhood: Diagnosis and treatment. Ortopedie 2002, 31, 1027–1038. [CrossRef]
50. Pilge, H.; Bittersohl, B.; Schneppendahl, J.; Hesper, T.; Zilkens, C.; Ruppert, M.; Krauspe, R.; Jäger, M. Bone marrow aspirate concentrate in combination with intravenous iloprost increases bone healing in patients with avascular necrosis of the femoral head: A matched pair analysis. Orthop. Rev. 2016, 8, 6902. [CrossRef] [PubMed]

51. Tillmann, F.P.; Jager, M.; Blondin, D.; Schooldermann, D.; Voiculescu, A.; Sucker, C.; Grabensee, B.; Krauspe, R.; Hetzel, G.R. Intravenous iloprost: A new therapeutic option for patients with post-transplant distal limb syndrome (PTDLS). Am. J. Transplant 2007, 7, 667–671. [CrossRef] [PubMed]

52. Tosun, H.B.; Uludağ, A.; Demir, S.; Serbest, S.; Yasar, M.M.; Öznam, K. Effectiveness of Iloprost in the Treatment of Bone Marrow Edema. Cureus 2020, 12, e10547. [CrossRef] [PubMed]

53. Der Simonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7, 177–188. [CrossRef]